Cancer Reports (Jun 2024)

A single‐centre study evaluating a geriatric screening tool in oncology phase I trial patients

  • Mary Van Zyl,
  • Anne Barell,
  • Bridget Cooley,
  • Janet Hanwell,
  • Josie Parlak,
  • Udai Banerji,
  • Johann De Bono,
  • Adam Sharp,
  • Juanita Lopez,
  • Nicolo Matteo Luca Battisti,
  • Anna Minchom

DOI
https://doi.org/10.1002/cnr2.2083
Journal volume & issue
Vol. 7, no. 6
pp. n/a – n/a

Abstract

Read online

Abstract Background Though cancer is more prevalent in the older population, this patient group are underrepresented in phase I oncology trials. Aims We evaluated the use of a geriatric screening tool (SAOP3) in patients of 70 years of age or older who attended a Phase I Clinical Trials Unit, with the aim of assessing the feasibility of the tool and identifying potential unmet needs in this patient group. Methods Twenty‐two patients over the age of 70 completed the SAOP3 questionnaire. Geriatric impairments and needs were analysed with descriptive statistics. Qualitative responses were grouped in themes using structured thematic analysis. Results All of patients triggered at least 1 geriatric domain, most commonly mobility. Six core themes were identified as being important to the patient including family, friends and positivity. On cognition assessment over 20% of patients triggered as requiring further cognitive assessment. The group had a relatively high screen fail risk. Conclusion In conclusion, routine geriatric screening withSAOP3 was feasible and identified areas of patient need. Results highlight the prevalence of psychological distress and cognitive impairment. Geriatric screening offers an opportunity for prehabilitation prior to trial and support during trial participation to optimise safety and improve trial access.

Keywords